Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068614 · ClinicalTrials.gov registry record · Phase 1
HER-2 Protein Vaccine in Treating Women With Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00068614 is a Phase 1 study of Breast Cancer that has completed, run by Case Comprehensive Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00068614, a Phase 1 study of Breast Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women who have breast cancer.
Conditions Studied
Interventions
- BIOLOGICAL HER-2/neu peptide vaccine
Study Locations (1)
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068614
The ClinicalTrials.gov registry entry for NCT00068614 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which HER-2/neu peptide vaccine is the first listed.
NCT00068614 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00068614 about?
NCT00068614 is a clinical study titled "HER-2 Protein Vaccine in Treating Women With Breast Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women who have breast cancer.
What is the current status of trial NCT00068614?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-07.
What conditions does trial NCT00068614 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00068614?
The interventions under investigation include: HER-2/neu peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00068614?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00068614 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.